Anbogen Therapeutics, Inc.
Update：2026/01/07
Industries
Main Industry
Biotechnology
Main Product/Service
Anbogen’s drug pipeline features two lead small‑molecule candidates: “ABT‑101,” a tyrosine kinase inhibitor targeting HER2 exon20 insertion mutations in non‑small cell lung cancer; and “ABT‑301,” an HDAC1/2/3 inhibitor designed for combination therapy wit
Founded Year
2019
Unified Business No.
82833776
Status
Active
Number of Employees
0
Total Paid-in
Capital
935,133,597 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Anbogen Therapeutics, Inc. is a Taipei‑based clinical‑stage biotech company focused on developing precision oncology drugs, with a mission to transform outcomes for cancer patients through innovative therapies.
